Format

Send to

Choose Destination
See comment in PubMed Commons below
Indian J Med Microbiol. 2016 Oct-Dec;34(4):516-519. doi: 10.4103/0255-0857.195370.

Pulmonary Mycobacterium kansasii disease in immunocompetent host: Treatment outcomes with short-course chemotherapy.

Author information

  • 1Department of Clinical Research, National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India.
  • 2Department of Bacteriology, National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India.

Abstract

Mycobacterium kansasii, most virulent of all atypical mycobacteria, causes pulmonary disease identical to the disease caused by Mycobacterium tuberculosis. Early identification of the species and prompt initiation of treatment for M. kansasii is necessary to prevent morbidity and mortality due to this disease. This case series highlights the similarity in the clinical presentation of both M. tuberculosis and M. kansasii and response to direct observation of short-course chemotherapy with rifampicin, in the management of pulmonary M. kansasii disease. Larger studies are required to evaluate the long-term effect of short-course chemotherapy, especially use of moxifloxacin, in the management of pulmonary M. kansasii disease.

PMID:
27934834
DOI:
10.4103/0255-0857.195370
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Medknow Publications and Media Pvt Ltd
    Loading ...
    Support Center